Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk ERBB2-Negative Breast Cancer: The I-SPY2 Randomized Clinical Trial.
Journal: JAMA oncology
Published: July 30, 2026
TILseg: Automated Whole Slide-Level Spatial Scoring of Tumor-Infiltrating Lymphocytes Reveals Prognostic Patterns in Triple Negative Breast Cancer.
Journal: medRxiv : the preprint server for health sciences
Published: February 06, 2026
Exploratory Analysis of the Impact of a Single Dose of Trastuzumab on the Immune Microenvironment in HER2-Positive Early-Stage Breast Cancer.
Journal: Biomedicines
Published: September 22, 2025
Axillary Management and Outcomes After Neoadjuvant Endocrine Therapy in the Randomized PELOPS Trial.
Axillary Management and Outcomes After Neoadjuvant Endocrine Therapy in the Randomized PELOPS Trial.
Journal: Annals of surgical oncology
Published: September 12, 2025
Adverse events in patients treated with neoadjuvant chemo/immunotherapy for triple negative breast cancer: results from seven academic medical centers.
Journal: Breast cancer research and treatment
Published: May 13, 2025
A phase Ib/II trial of atezolizumab with cobimetinib or idasanutlin in metastatic estrogen receptor positive breast cancer.
Journal: NPJ breast cancer
Published: December 20, 2024
In Situ Detection of Individual Classic MHC-I Gene Products in Cancer.
Journal: Cancer immunology research
Published: October 14, 2024
Associations of Immune Checkpoint Predictive Biomarkers (MHC-I and MHC-II) with Clinical and Molecular Features in a Diverse Breast Cancer Cohort.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 23, 2024
Liquid Biopsy Assessment of Circulating Tumor Cell PD-L1 and IRF-1 Expression in Patients with Advanced Solid Tumors Receiving Immune Checkpoint Inhibitor.
Journal: Targeted oncology
Published: May 07, 2022
New targets in endocrine-resistant hormone receptor-positive breast cancer.
Journal: Clinical advances in hematology & oncology : H&O
Published: August 19, 2021
Quantification of Human Epidermal Growth Factor Receptor 2 by Immunopeptide Enrichment and Targeted Mass Spectrometry in Formalin-Fixed Paraffin-Embedded and Frozen Breast Cancer Tissues.
Journal: Clinical chemistry
Published: November 10, 2020
Last Updated: 09/26/2026